

Documents

- 1) Shuli, Z., Linlin, L., Li, G., Yinghu, Z., Nan, S., Haibin, W., Hongyu, X.

Bioinformatics and Computer Simulation Approaches to the Discovery and Analysis of
(2022) *Current Pharmaceutical Biotechnology*, 23 (13), pp. 1541-1555.

- 2) Pérez-Rubio, G., Ponce-Gallegos, M.A., Domínguez-Mazzocco, B.A., Ponce-Gallegos, J., García Valencia, R.

Role of the host genetic susceptibility to 2009 pandemic influenza A H1N1
(2021) *Viruses*, 13 (2), art. no. 344, .

- 3) Ge, C., Zhang, W., He, R., Cai, H.

Systematic Identification and Comparative Analysis of Human Cartilage-Derived Self-peptides by Ankylosing Spondylitis (AS)-Associated HLA-B*27:05 and Non-AS-associated HLA-B*27:05
(2020) *International Journal of Peptide Research and Therapeutics*, 26 (1), pp. 513-522.

- 4) Wu, L.

Chapter 1: Regulatory Considerations for Peptide Therapeutics
(2019) *RSC Drug Discovery Series*, 2019-January (72), pp. 1-30.

- 5) Mohammadi, M., Falak, R., Esmeh, R.Z., Maleki, S.J., Kardar, G.A.

Computational analysis of specific IgE epitopes responsible for allergy to fish
(2018) *Current Immunology Reviews*, 14 (2), pp. 130-136.

- 6) Wu, L.C., Chen, F., Lee, S.L., Raw, A., Yu, L.X.

Building parity between brand and generic peptide products: Regulatory and scientific aspects of synthetic peptides
(2017) *International Journal of Pharmaceutics*, 518 (1-2), pp. 320-334.

- 7) Schrörs, B., Lübcke, S., Lennerz, V., Fatho, M., Bicker, A., Wölfel, C., Derigs, P., Hankeln, T., Wölfel, T.
HLA class I loss in metachronous metastases prevents continuous T cell recognition c human melanoma model
(2017) *Oncotarget*, 8 (17), pp. 28312-28327.
- 8) Wang, Y., Zhou, P., Lin, Y., Shu, M., Hu, Y., Xia, Q., Lin, Z.
Quantitative prediction of class i MHC/epitope binding affinity using QSAR modeling d structural information
(2015) *Combinatorial Chemistry and High Throughput Screening*, 18 (1), pp. 75-82.
- 9) Liu, S., Liu, S., Wang, Y., Liao, Z.
The P2/P2' sites affect the substrate cleavage of TNF- α converting enzyme (TACE)
(2014) *Molecular Immunology*, 62 (1), pp. 122-128.
- 10) Flower, D.R.
Designing immunogenic peptides
(2013) *Nature Chemical Biology*, 9 (12), pp. 749-753.
- 11) Fulton, K.M., Twine, S.M.
Immunoproteomics: Current technology and applications
(2013) *Methods in Molecular Biology*, 1061, pp. 21-57.
- 12) Nirmala, S., Sudandiradoss, C.
Prediction of promiscuous epitopes in the e6 protein of three high risk human papillo approach
(2013) *Asian Pacific Journal of Cancer Prevention*, 14 (7), pp. 4167-4175.
- 13) Ren, Y., Tian, F., Zhou, P.
Computational peptidology
(2012) *Progress in Chemistry*, 24 (9), pp. 1674-1682.

14) Fadda, L., Körner, C., Kumar, S., van Teijlingen, N.H., Piechocka-Trocha, A., Carrington, M.,

HLA-Cw*0102-restricted HIV-1 p24 epitope variants can modulate the binding of the in and primary NK cell function

(2012) *PLoS Pathogens*, 8 (7), art. no. e1002805, p. 40.

15) Knapp, B., Giczi, V., Ribarics, R., Schreiner, W.

PeptX: Using Genetic Algorithms to optimize peptides for MHC binding

(2011) *BMC Bioinformatics*, 12, art. no. 241, .

16) Li Pira, G., Ivaldi, F., Moretti, P., Manca, F.

High throughput T epitope mapping and vaccine development

(2010) *Journal of Biomedicine and Biotechnology*, 2010, art. no. 325720, .

ELSEVIER

Copyright © 2024 Elsevier B.V. All rights reserved. Scopus® is a re
trademark of Elsevier B.V.